Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ELCC 2026
Top resúmenes y presentaciones
A phase I dose escalation trial of obrixtamig + ezabenlimab
in patients (pts) with small cell lung cancer (SCLC) or other
neuroendocrine carcinomas (NECs) expressing DLL3
409O
Updated results for MK-1084 + pembrolizumab in KRAS
G12C-mutated (mut) metastatic non-small cell lung
cancer (mNSCLC) enrolled in KANDLELIT-001
4MO
Efficacy and safety of setidegrasib in patients with advanced
NSCLC with KRAS G12D mutation
1O
Phase II ETOP ADEPPT trial: Adagrasib in patients with
KRASG12C-mutant NSCLC who are elderly or have poor
performance status - Final results
5MO
Zongertinib in treatment-naïve patients with HER2-mutant
NSCLC, including those with active brain metastases:
Beamion LUNG-1
6MO
ELCC 2026
MUTACIONES DRIVER Y TEMPRANO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
First-line clinical outcomes of single versus compound
EGFR PACC mutations in advanced NSCLC: An
international multicentre study
43P
First-line lorlatinib versus sequential second-generation
ALK TKI followed by lorlatinib in advanced ALK-positive
non-small cell lung cancer: A real-world cohort study
48P
Becotarug (JMT101) and osimertinib (Osi) in patients (pts) with
platinum-pretreated EGFR exon 20 insertion-mutated (ex20ins)
non-small cell lung cancer (NSCLC): Final overall survival (OS)
and subgroup analyses from the BECOME phase II study
7MO
Neoadjuvant divarasib shows manageable safety and
promising activity in patients with resectable, early-stage,
KRAS G12C+ NSCLC: First results from the NAUTIKA1 KRAS
G12C+ cohort
238P
ELCC 2026
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
MUTACIONES DRIVER Y TEMPRANO